Nanoptima

Developer of drug delivery technology for retinal diseases

placeAlderley Edge, England, United Kingdom calendar_todayFounded 2016 groups1 employees language nanoptima.com

Registered entities

Innovation

2 patent families; filing pace steady.

YearFilings
20211
20251

Investor mix

5 investors on record; lead investors include Deepbridge Capital.

Investor typeCountShare
Venture capital120%
Private equity120%
Other / undisclosed360%
Coming soon